GENOSS Showcases 3D-Printed Spinal Implants at 27th Korean Spinal New Technology Society Conference

GENOSS Co., Ltd., a South Korean medical device manufacturer, presented its 3D-printed spinal implant portfolio at the 27th Korean Spinal New Technology Society conference held on July 4, 2026, at the Grand Walkerhill Hotel in Seoul. The company exhibited its 3D Cervical Cage, 3D Lumbar Cage, Cervical Plate, and spinal screws, alongside its PDRN-based wound care products. GENOSS used the event to gather clinical feedback from spine surgeons and to demonstrate the design flexibility and osseointegration potential of its additively manufactured titanium implants. The company also confirmed it is preparing to launch an Anterior Cervical Plate and related follow-on products in the general hospital segment, aiming to broaden its spine product lineup beyond specialized academic centers.

This event fits within the broader medical-dental vertical, where metal PBF-LB (LPBF) has become the dominant process for producing porous titanium spinal cages and plates. GENOSS is competing in a segment already populated by established players such as CoreLink, NuVasive, and Medtronic, as well as Korean peers like T&L and CGBio. The company’s strategy of using 3D-printed porous structures to promote bone ingrowth mirrors the industry-wide shift from machined titanium implants to additively manufactured designs with controlled lattice architectures. By engaging directly with surgeons at a focused academic conference rather than a broad trade show, GENOSS is following the proven qualification pathway for spinal implants: building clinical references one surgeon at a time, rather than relying on marketing volume. The company’s emphasis on expanding from specialized academic hospitals into general hospitals signals a deliberate scaling strategy, moving from early-adopter surgeons to broader institutional adoption.

From an industry perspective, this is a routine but strategically sound product showcase. GENOSS is not introducing breakthrough technology - porous titanium cages are now standard in spinal surgery - but it is executing the necessary clinical engagement and product-line expansion that turns a design capability into a sustainable business. The company’s next milestone will be securing formal regulatory approvals (MFDS in Korea, and potentially FDA 510(k) for export) and demonstrating consistent manufacturing quality across its 3D-printed implant line. For buyers and surgeons, the key differentiator will be the quality of the porous structure, the consistency of mechanical properties across production batches, and the clinical outcomes data GENOSS can generate from its early-adopter sites.